Why did GAAP EPS decline while adjusted EPS grew strongly?

GAAP EPS of $1.67 was down from $1.76 due to $0.44 per share in net costs for significant litigation and $0.28 in other special items, including divestiture costs related to the Solventum spin. Adjusted EPS excludes these items and rose to $2.39 from $1.97, reflecting higher operating margins, particularly in Transportation and Electronics and Safety and Industrial.

How does the Solventum spin-off affect 3M's future financial reporting and guidance?

Beginning in Q2 2024, Solventum's historical results will be reported as discontinued operations. The 2024 guidance reflects Solventum as discontinued for the full year, including Q1, so guidance is on a continuing-operations basis and is not directly comparable to prior reported figures. Illustrative 2023 adjusted EPS on this basis is roughly $5.97 to $6.12, compared with $9.24 as originally reported.

What are the financial implications of the PFAS and Combat Arms Earplug settlements?

The public water supplier settlement carries a pre-tax present value commitment of up to $10.3 billion payable over 13 years, and the Combat Arms Earplug settlement totals up to $6.0 billion (about $5.3 billion present value) through 2029. 3M has previously recorded reserves for both, so the finalization primarily affects the timing of cash outflows, which will weigh on free cash flow in the coming years. Net debt rose to $10.4 billion and total debt to $21.4 billion as of March 31, 2024.

Is the dividend at risk following the spin-off?

3M paid $835 million in dividends in Q1 2024. Going forward, management expects the dividend payout ratio to be about 40% of adjusted free cash flow, with the Q2 dividend expected to be declared in May 2024 subject to board approval. Given the lower post-spin cash generation profile and substantial settlement payments, investors should watch whether the dividend level is reset relative to the new base.

What should investors watch in the near term?

Key items include the Q2 2024 dividend declaration, the first results and guidance updates under the new CEO Bill Brown beginning May 1, 2024, the pace of cash outflows from litigation settlements, the monetization of the retained 19.9% Solventum stake, and whether the company can deliver its adjusted organic growth range of flat to +2% for the full year.

MMM 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 30, 2024. Cited figures are marked; the original filing is the authoritative source.

3M reported first-quarter 2024 results on April 30, 2024, with sales of $8.0 billion^a (down 0.3% YoY, organic sales flat) and GAAP EPS of $1.67 (down 5% YoY).

Adjusted EPS rose 21% to $2.39^b and the adjusted operating income margin expanded 4.0 points to 21.9%, though these results are inclusive of the Health Care business, which was spun off as Solventum (NYSE: SOLV) on April 1, 2024. Results were driven largely by Transportation and Electronics and Safety and Industrial, while Consumer declined. Cash flow was weak on a GAAP basis, with operating cash flow of $767 million versus $1,275 million a year earlier, and adjusted free cash flow was $833 million.

Net debt rose to $10.4 billion, and total debt increased to $21.4 billion^c after the spin-related financing. The filing also finalized two major litigation settlements: the public water supplier PFAS settlement (up to $10.3 billion pre-tax present value over 13 years, received final court approval March 29) and the Combat Arms Earplugs settlement (up to $6.0 billion through 2029, or $5.3 billion present value), both of which had previously been reserved. Management initiated 2024 guidance on a continuing-operations basis, forecasting adjusted EPS of $6.80 to $7.30, flat to +2% adjusted organic sales growth, and adjusted total sales growth of (0.25%) to +1.75%.

The company also announced that William "Bill" Brown will succeed Mike Roman as CEO effective May 1, 2024, with Roman becoming Executive Chairman. Investors should note that the guidance is not directly comparable to prior-year GAAP results, and the retained 19.9%^d Solventum stake is expected to be monetized within five years.

The headline GAAP EPS decline and the large litigation charges (net costs for significant litigation of $0.44 per share in Q1) mean that adjusted metrics, which exclude these items, should be reviewed alongside GAAP figures. The dividend payout target of approximately 40% of adjusted free cash flow and the Q2 dividend declaration in May 2024 will be key items for income-focused shareholders to monitor.

02—Key points

Key Highlights

Q1 2024 GAAP EPS of $1.67 (down 5% YoY) versus adjusted EPS of $2.39 (up 21% YoY), with a $0.44 per-share net litigation cost as the main special item
Sales of $8.0 billion (down 0.3% YoY); adjusted sales of $7.7 billion (up 0.5%) with adjusted organic growth of 0.8%
Adjusted operating margin expanded 4.0 points to 21.9%; Transportation and Electronics adjusted EBITDA margin rose to 30.8% from 21.2%
Completed the spin-off of Solventum (SOLV) on April 1, 2024; 3M retained a 19.9% stake to be monetized within five years
Finalized the public water supplier PFAS settlement (up to $10.3B pre-tax present value over 13 years) and the Combat Arms Earplugs settlement (up to $6.0B through 2029)
2024 adjusted EPS guidance of $6.80 to $7.30 on a continuing-operations basis, with flat to +2% adjusted organic sales growth
Leadership transition: Bill Brown becomes CEO May 1, 2024; Mike Roman becomes Executive Chairman; dividend payout target set at ~40% of adjusted free cash flow

03—Questions

Frequently Asked Questions

Why did GAAP EPS decline while adjusted EPS grew strongly?
GAAP EPS of $1.67 was down from $1.76 due to $0.44 per share in net costs for significant litigation and $0.28 in other special items, including divestiture costs related to the Solventum spin. Adjusted EPS excludes these items and rose to $2.39 from $1.97, reflecting higher operating margins, particularly in Transportation and Electronics and Safety and Industrial.
How does the Solventum spin-off affect 3M's future financial reporting and guidance?
Beginning in Q2 2024, Solventum's historical results will be reported as discontinued operations. The 2024 guidance reflects Solventum as discontinued for the full year, including Q1, so guidance is on a continuing-operations basis and is not directly comparable to prior reported figures. Illustrative 2023 adjusted EPS on this basis is roughly $5.97 to $6.12, compared with $9.24 as originally reported.
What are the financial implications of the PFAS and Combat Arms Earplug settlements?
The public water supplier settlement carries a pre-tax present value commitment of up to $10.3 billion payable over 13 years, and the Combat Arms Earplug settlement totals up to $6.0 billion (about $5.3 billion present value) through 2029. 3M has previously recorded reserves for both, so the finalization primarily affects the timing of cash outflows, which will weigh on free cash flow in the coming years. Net debt rose to $10.4 billion and total debt to $21.4 billion as of March 31, 2024.
Is the dividend at risk following the spin-off?
3M paid $835 million in dividends in Q1 2024. Going forward, management expects the dividend payout ratio to be about 40% of adjusted free cash flow, with the Q2 dividend expected to be declared in May 2024 subject to board approval. Given the lower post-spin cash generation profile and substantial settlement payments, investors should watch whether the dividend level is reset relative to the new base.
What should investors watch in the near term?
Key items include the Q2 2024 dividend declaration, the first results and guidance updates under the new CEO Bill Brown beginning May 1, 2024, the pace of cash outflows from litigation settlements, the monetization of the retained 19.9% Solventum stake, and whether the company can deliver its adjusted organic growth range of flat to +2% for the full year.

04—Continue

← View all 8-K filings